Farmaci d’urgenza
"#$%%&'()* +&),& -$))&..& %-0(1$%&'()*%+,+%$,+%&%-.#%/ """#$%&'()*%+,+%$,+%&%-.#%/
234564728 9+',-.:%-. 3('.+',-.:%-. ;(<*/.$%-. ;(=.$%-.
9352>69;2B96;2B28 9/'(=%-. 2D(=',-.:%-. 935259BE2B96;2B28 7'(=.0,-(-, 9$%(+.'(-, F(/.:(:( ;%)(DD%-.
>?59@>A4BB93528 9/,-(:(:( C,/(='(:(:( 7'(='.-(:(:( A.<,/.:(:(
B.@9359G432F528
;%:/%.H,$
I,'.=.$%:
;2J6?52B2 ? 32564;?62I9528
K*'(D,$%+,
3%/'():%&,'%-.
3%/'(='*DD%./(
234564728 9+',-.:%-. 3('.+',-.:%-. ;(<*/.$%-. ;(=.$%-.
9352>69;2B96;2B28 9/'(=%-. 2D(=',-.:%-. 935259BE2B96;2B28 7'(=.0,-(-, 9$%(+.'(-, F(/.:(:( ;%)(DD%-.
>?59@>A4BB93528 9/,-(:(:( C,/(='(:(:( 7'(='.-(:(:( A.<,/.:(:(
B.@9359G432F528
;%:/%.H,$
I,'.=.$%:
;2J6?52B2 ? 32564;?62I9528
K*'(D,$%+,
3%/'():%&,'%-.
3%/'(='*DD%./(
9A5628 9$%-(0%::%-. F($./(D/./%-. ?=.'%-. F(+%&. 5'($<(:%/%&%
"//0123"435637 79 L 7',DD%(-, 9'/,'%(D. KB L K',M*,-H. B.'+%.&. ?BG L ?:,//'(&.'+%()'.$$. KI L K%<'%::.H%(-, I,-/'%&(:.', 5I L 5.&N%&.'+%. I,-/'%&(:.', 7?9 L 9//%O%/P ?:,//'%&. F,-H. 7(:D( FK L F(:*H%(-, K%D%(:()%&. QRST FG L F(:*H%(-, G:*&(D./. UT K9 L K%<'%::.H%(-, 9/'%.:, >9I L >:(&&( 9/'%(@I,-/'%&(:.', >F9 L >:(&&( F,-( 9/'%.:, 5FI L 5.&N%&.'+%. F(='.I,-/'%&(:.', 57FI L V(:00 7.'W%-D(- VN%/, FFF L F%&W F%-*D FX-+'($, 7C L 7.&,$.W,' 2C9 L 2-0.'/( C%(&.'+%&( 9&*/( >7B4 L >'(-&(=-,*$(=./%. B'(-%&. 4D/'*//%O. ?79 L ?+,$. 7(:$(-.', 9&*/( ?7 L ?$<(:%. 7(:$(-.', GB L G%//./. B.'+%.&. B2; L B(.)*:.H%(-, 2-/'.O.D&(:.', ;%DD,$%-./. F5?C2 L F5 ?:,O./%(- C%(&.'+%.: 2-0.'&/%(32EFF L 3./%(-.: 2-D/%/*/, (0 E,.:/N F/'(W, F&.:,
!"#$%!&'%!
Y$)ZY$: [9+',-.:%-.\ Y8YQQQ
;(D.))%(8 O,+% /.<,::. !""#$$% ' ())#*(+$% Effetto max: 3’
3'(,8&.,*',8 9'',D/( &.'+%.&( +. KI ( 5IR .D%D/(:%.R 7?9 9-.0%:.DD% 9*':)*,'(,8&.,*',8 G:.*&($. .+ .-)(:( &N%*D(
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% B.'+%(=./%. %D&N,$%&.R +%.<,/,R %=,'/,-D%(-, 2-D*00%&%,-H. &,',<'(@O.D&(:.', 2=,'/%'(%+%D$( 5(DD%&%/P +%)%/.:%&. [%-/,'.H%(-,\ "==$):$'.$8 C(-%/('%HH.', 79R KBR ?BG 3(- $,D&(:.', &(- D(D/.-H, .:&.:%-, I,-. +% )'(DD( &.:%<'( ( =,' O%. ,-+(/'.&N,.:,
>5?"@@3 ">016"A36" ,-./-0.1-2/! 3.,4-252602/.,! 78 # 98 .:(:$%;(+ % 5!.
! #$ %&'& ()*) +$ ,- ./)01 2,- 0+0$) (+ 3456 *)+ ! #$ %&'& 7 0+0$+ 7$8%9:+ 2);:+ ,<= >+:?8+6 ! #$ %&'& 7**%:7 *)..+@+$% *)+ ! #$ %&'& 7 0+0$+ 7$8%9:+ 2);:+ ,<= >+:?8+6
./.9-6.<<2(7 .)>>+:+.8979% +: 07.) (+ 7$8%97A+):+ (%$$% '+% 7%9%%B *)$>):79+ ) 0+90)$78)9+% 7 9+.0/+) *%9 $7 '+876 -/7,.0=<326.,! 8%9A) >%(+) (%$$7 0).0+7 +: 7:8%9)$78%97$% 2*+C .+0?97B :): 9+0/+%(% 700%..+ '%:).+6 .*>;$( ?@@ )AB C@D? ); *( "; E'E@@@F G+)H(I( J EK +II( ?@@ )AB C@D? ); *( "; E'E@@@F G+)H(I( LMEK +II( N@@ )AB C@DN ); *( "; E'E@@@F G+)H(I( O L +II( E?@ )AB C@DE? ); *( "; E'E@@@F ,(P#$#Q# *%P% ? )(I>$( :# I% )(B;(%Q+)#I$% !/428!/. D7 #$ !E!FFF 2!>; +: ! >$6 '7 GHI53H (+$?+87 2 ↑ RISCHIO di effetti collaterali se diagnosi sbagliata 6 5%Q$+Q# E "; *+ E )B + E@ ); C:%;>R(%I# E'E@@@@F .*>;$( ?@ )AB C@D? ); *( :%;>R(%I# E'E@@@@F G+)H(I( E )ABSTB C@D@E );STB *( :%;>R(%I# E'E@@@@F
%)#!"#$%!&'%!
]$)ZY$: [3('.+',-.:%-. /.'/'./(\
;(D,8 O,+% /.<,::. !""#$$% ' EM2’
3'(,8&.,*',8 FN(&W &.'+%(),-( FN(&W D,//%&( 955?3^243?8 -(- +% ='%$. :%-,.R %-+%&./( %- .DD(&%.H%(-, . :%M*%+% , %-(/'(=% [+(<*/.$%-.\ D, M*,D/% *:/%$% 0.::%D&(-( nell’aumentare la PA. 9*':)*,'(,8&.,*',8 5'($<(D% .'/,'%(D, [O.D(&(D/'%H%(-,\ 2=,'&.=-%. , %=(DD%. )'.O,
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% B.'+%(=./%. %D&N,$%&. ( O.D&(:(=./%. =,'%0,'%&. [I.D(&(D/'%H%(-,\ 2=,'/,-D%(-, 2=,'/%'(%+%D$( ?O%/.', DD(&%.H%(-, &(- ;(=.$%-. .+ .:/% +(D.))% [N. )%P ,00,//( O.D(=',DD('%(\ 5,'.=%. &(- .-/%+,=',DD%O% /'%&%&:%&% "==$):$'.$8 C(-%/('%HH.', 79R KBR ?BG 7'(/,)),', +.::. :*&, 2n caso di stravaso → 5@YQ$) +% 0,-/(:.$%-. %- YQ && +% FK
>5?"@@3 650">016"A36" 4%:+BB(% (I(R(+;#' @D?ME )ABS)(I .BB(>:$+)#I$(' ↑ E )ABS)(I %BI( ?M10’ #+:) 7 9+.*).87 %>)(+:7>+07 956 +3905@59935A"B501 E"; (I K?@AA *( <9 CU)ABS);F J).7;;+) 2>0;K>+:6 L MB= V );SW *+ (I"%I*#Q# 4%:+BB(% (I(R(+;# @D?ME )ABS)(I 5#Q %BI( (IAQ#)#I$% *( E )ABS)(I 4%:+BB(% )+Y N@ )ABS)(I
XMU );SW ↑ 8 ml/h KK? );SW
956 POMPA D’INFUSIONE E"; (I ?@AA *( <9 CX@)ABS);F J).7;;+) 2>0;K>+:6 L FBNN V );SW *+ (I"%I*#Q# 4%:+BB(% (I(R(+;# @D?ME )ABS)(I 5#Q %BI( (IAQ#)#I$% *( E )ABS)(I 4%:+BB(% )+Y N@ )ABS)(I
@DNM@DL );SW ↑ 0,6 ml/h K@ );SW
")*+,!-'%!
;(D,8 O,+% /.<,::.
]UQ$)Z]Q$: [;(<*/',_\
!""#$$% ' EM2’ !""#$$ o max: 10’→10’
3'(,8&.,*',8 F*==('/( %-(/'(=( +% <',O, =,'%(+( %- =.H%,-/% &(- 8 F&($=,-D( &.'+%.&( . <.DD. =('/./. [,#)# ?79 &(- <.DD. =('/./.R DN(&W &.'+%(),-(\ FN(&W D,//%&(R 96;F ?$<(:%. =(:$(-.', $.DD%O. ['%+*&, :, ',D%D/,-H, =(:$(-.'%\ 9*':)*,'(,8&.,*',8 F/,-(D% %=,'/'(0%&. D(//(.('/%&. 2- /,'.=%. %D(:./. %- =.H%,-/% %=(O(:,$%&%
;)$8&<.,*',8 B.*/,:. %- =',D,-H. +% K9 "==$):$'.$8 a C(-%/('%HH.', 79R KBR ?BGR ` [=*b +.', %=(`.:%,$%.\ 3(- D($$%-%D/'.', &(- 79cSQ $$E) , %=(O(:,$%.
>5?"@@3 >5/CB"+36" 4%:+BB(% (I(R(+;#' KD?)ABSTBS)(I Aggiustamenti:↑2,5mcg/Kg/min ogni 10 M15’ #+:) 7 9+.*).87 %>)(+:7>+07 4%:# )+::()+' !=>0;KO;K>+: 2PF >0;KO;K>+: +: *7A+%:8+ @%87@$)0078+6 .77!/1-2/!' :%:P#I*#Q# BQ+*>+;)#I$# 956 +3905@59935A"B501 E"; (I K?@AA *( <9 CE)BS);F J).7;;+) 2>0;K>+:6 L *%.) 2O;6 L FBFN V );SW *+ (I"%I*#Q# )ABSTBS)(I KD? ? E@ ?@ TB L@ TB Z@ TB [@ TB
ZD? );SW [ );SW E@D? );SW END? );SW
E? );SW EU );SW KE );SW KZ );SW
N@ );SW NL );SW XK );SW ?X );SW
956 POMPA D’INFUSIONE E"; (I ?@AA *( <9 C?)BS);F J).7;;+) 2>0;K>+:6 L *%.) 2O;6 L FBF!P V );SW *+ (I"%I*#Q# )ABSTBS)(I KD? ? E@ ?@ TB L@ TB Z@ TB [@ TB
ED? );SW EDU );SW KDE );SW KDZ );SW
N );SW NDL );SW XDK );SW ?DX );SW
L );SW ZDK );SW UDX );SW E@DU );SW
").!-'%!
;(D,8 O,+% /.<,::.
]QQ$)ZU$: [6,O%O.-\
!""#$$% ' KM5’ !""#$$% )+Y'10’ →10’
3'(,8&.,*',8 Q7..) ().7;;+)8 *%P+)(I#QB(A+ C\+:%*(;+$+R(%I#F ↓gittata cardiaca con compromissione renale (oliguria) J).7;;+) >%(+) ) %$%'78)8 β -+*Q#I#QB(A% C(I%$Q%P%F ed αM +*Q#I#QB(A% C\+:%A%:$Q(R(%I#F
9*':)*,'(,8&.,*',8 K,(&'($(&%/($. 2- /,'. %. %D(:./. %- .H % (O(:,$%&%
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% B.'+%(=./%. %D&N,$%&.d O.D&(:(=./%. =,'%0,'%&. [I.D(&(D/'\ 9'%/$%, $%-.&&%(D, [='(.'%/$%&(\ "==$):$'.$8 C(-%/('%HH.', 79R KBR ?BG
4%:+BB(% Q#I+;#' K )ABSTBS)(I 4%:+BB( )#*(%M+;$(' ?ME@ )ABSTBS)(I E"; (I K?@AA *( <9 C@DU)BS);F J).7;;+) 2>0;K>+:6 L *%.) 2O;6 L FBFM= V );SW *+ (I"%I*#Q# )ABSTBS)(I K ? E@ ?@ TB ZD? );SW EUDZ? );SW NZD? );SW L@ TB [ );SW KKD? );SW X? );SW Z@ TB E@D? );SW KLDK? );SW ?KD? );SW [@ TB END? );SW NNDZ? );SW LZD? );SW
!,#).'%!
Y$)ZY$: [9/'(=%-. D(:0./(\
;(D,8 1mg → ripetibile a 5’ ;(D, $._' @D@X)BSTB CA(QA+ N)BF !""#$$% ' 2’ ! #$$% )+Y' KMX’→45’
3'(,8&.,*',8 >'.+%&.'+%, , >9I 2=(/,-D%(-, +. %=,'/(-( O.).:,
9*':)*,'(,8&.,*',8 F/,-(D% =%:('%&.R %:,( =.'.:%/%&(R &(:%/, *:&,'(D. )'.O, G:.*&($. .+ .-)(:( &N%*D( C%.D/,-%. )'.O%D
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% Febbre → non permette la sudorazione→Ipertermia "==$):$'.$8 C(-%/('%HH.', 79R KBR ?BG 2- &.D( +% D(='.+(D.))%o → Neostigmina (0,5@]$) ,#O#\
'/).#$%!&'%!
;(D,8 O,+% /.<,::.
QR] $)ZY$: [2D(=',-.:%-. &:('%+'./(\ !""#$$% ' ())#*(+$% Effetto max: 15’→1h 3'(,8&.,*',8 >'.+%&.'+%, ,$(+%-.$%&.$,-/, D%)-%0%&./%O,R ',D%D/,-/% .::. ./'(=%-. [G;%AAW( :%$$%W(:(+I( \ 5('D%(-, +% =*-/.
9*':)*,'(,8&.,*',8 2D&N,$%. $%(&.'+%&. 5.&N%.'%/$%, 5(DD%&%/P +%)%/.:%&.
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% 2=(O(:,$%&% [=*b +.', %=(/,-D%(-,\ "==$):$'.$8 C(-%/('%HH.', 79R KBR ?BG
>*%&DD,*7 EFGH I8DJI,' ? "; (I E@@AA *( <9 CE@)ABS);F J).7;;+) 2>0;K>+:6 L N V );SW *+ (I"%I*#Q# )ABS)(I );SW )ABS)(I );SW E L EK ZK K EK E? [@ ? N@ EU E@U E@ L@ K@ EK@
.#).!0$%)%$
;(D,8 =$(, :&K$##&
eQ$)Z]Q$: [6X/$(-('$\ 3'(,8&.,*',8 5FI [K:*//,' 9/'%.:,R K9R 57FI\ 9'%/$%, %- =',D,-H. +% V7V
!""#$$% ' 1’ !""#$$% )+Y' 10’ →20 MN@ ’
9*':)*,'(,8&.,*',8 2-D*00%&%,-H. &.'+%.&. , DN(&W &.'+%(),-(R 79cYQQ [%-( @\ FFFR >9I +% 22 , 222R >>F- , >:(&&N% 0.D&%&(:.'%R KBcUQ ? ./( ./%. '.O, C%.D/,-%. >7B4
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% 2-D*00%&%,-H. &.'+%.&. -(- )'.O, 2-D*00%&%,-H. ,=./%&. [$,/.<(:%D$( ,=./%&(\ "==$):$'.$8 C(-%/('%HH.', 79R KBR ?BG B('',)),', ,:,//'(:%/% ='%$. Se QRS ↑ > 18% → ↓ dose Se ↓ PA o FC → do amina e iso roterenolo
>*%$ ,',.,&#$7 G IDJLD ,' MFEH’
+&':$',I$':*7 HNHHO IDJLDJI,'
Y 0: %- ]UQ&& 0: %- <(:( +% F(: G:*& UT ?@ TB E]ESK "; Z? );SW Z@ TB K "; E@? );SW [@ TB K]ESK "; EN? );SW R): .?*%979% P )9% (+ +:#?.+):% (+ >7:8%:+>%:8)
(==*', ]UQ&& +% F(: G:*& UT a ^ "; E"; E"; # _"; 7 !P= >$K/ 2P )9%6
!-')"!#)%$
;(D,8 =$(, :&K$##&
YUQ$)Zf$: [B('+.'(-,\ !""#$$% ' 10’ !""#$$% )+Y' N@ML@ ’ 3'(,8&.,*',8 5FI [K:*//,' 9/'%.:,R K9R 57FI\R 5I 6.::,-/.$,-/( +,::. K',M*,-H. I,-/'%&(:.', %- &('D( +% 0:*//,' ( K9 7'(0%:.DD% +% ',&%+%O, +% .'%/$%, O,-/'%&(:.'%
9*':)*,'(,8&.,*',8 2=(/,-D%(-, FFFR >9I +% 22 , 222 %- .DD,-H. +% 7C
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% 2=(/,-D%(-, 2-D*00%&%,-H. ,=./%&. [$,/.<(:%D$( ,=./%&(\ 5%',(=./%, [&(-/%,-, %(+%(\ "==$):$'.$8 C(-%/('%HH.', 79R KBR ?BG ;%:*%', F?C76? %- F(:*H%(-, ):*&(D./. [FG\
>*%$ ,',.,&#$7 PFM IDJLD ,' MFEH’
+&':$',I$':*7 EM IDJLDJGQR
0: %- <(:( g 0: %- ]UQ&& +% FG ?@ TB E]ESK "; EN );SW Z@ TB K "; EU );SW [@ TB K]ESK "; KN );SW S$ @)$) *?T %..%9% #788) 7:0/% +: ?:7 #$%@) (+ GU +: ,F >+:
/),!&)&)
;(D,8 =$(, :&K$##&
gQ$)Zg$: [6X/$(<,/.\
!""#$$% ' KM?’ !""#$$% )+Y' N@ ’ →LW
3'(,8&.,*',8 K:*//,' ./'%.:, [$.))%(' ,00%&.&%.\R 5I 9'%/$%, .DD(&%./, . V7V
9*':)*,'(,8&.,*',8 2-D*00%&%,-H. &.'+%.&.R DN(&W &.'+%(),-( FFFR >9I +% 22 , 222 %- .DD,-H. +% 7CR KBcUQ <=$ h5 :*-)( 9D$. <'(-&N%.:,
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% I.D&(:(=./%. =,'%0,'%&. 2-D*00%&%,-H. ',-.:,R %=(`.:%,$%. 5%',(/(DD%&(D%R 0,(&'($(&%/($. ;%.<,/,# "==$):$'.$8 C(-%/('%HH.', 79 KB ?BG
>*%&DD,*7 ENMIDJSD in 10’ ;$%* TSDU 6
E]` E]^ K]_ K]^ N N]_
"'1)//'%!
;(D,8 =$(, :&K$##&
QRU$)Z]$: [A.-(_%-\
!""#$$% ' ?M10’ !""#$$% )+Y' KW
3'(,8&.,*',8 ↓ della Freq V,-/'%&(:.', -,::, /.&N%.'%/$%, ./'%.:% %=',D,-H. +% D&($=,-D( &.'+%.&( 9*':)*,'(,8&.,*',8 V7V ['%D&N%( +% +,),-,'.H%(-, +% *-. K9 %- KI\ FFFR >F9R >9I +% )'.+( ,:,O./(
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% 6%+(//. 0*-H%(-, ',-.:, C%(&.'+%/, .&*/.R 2C9 a aa aa ↓K , ↓Mg , ↑Ca , Ipossia, Ipotiroidismo (↑ EFFETTO) "==$):$'.$8 Fomministrare lentamente (5’) → rischio di vasocostriz %(-, B(-/'(::.', 0*-H%(-, ',-.:,R ,:,//'(:%/%R ?BGR +%)(DD%-,$%. B.'+%(O,'D%(-, ,:,//'%&.8 D(D=,-+,', ]g N ='%$.
>*%$ ,',.,&#$7
HNGMFHNMID TEJGFEV#U in 5’
+&':$',I$':*7
HNHEFHNHGIDJSD ,' GF3 boli ev di 5’
!,$%)&)&)
;(D,8 =$(, :&K$##&
U$)ZYQ$: [5,-('$%-\
!""#$$% ' 5’ !""#$$% )+Y' E?’ →18 MKXW
3'(,8&.,*',8 %D&N,$%. $%(&.'+%&. ,+ 2C9 [%- =.H#,$(+%-.$%&.$,-/, D/.<%:%\ 5.&N%.'%/$%, I,-/'%&(:.'% , F(='.O,-/'%&(:.'% 2=,'/,-D%(-, .'/,'%(D. %- =',D,-H. +% +%DD,H%(-, .('/%&. 9*':)*,'(,8&.,*',8 2-D*00%&%,-H. &.'+%.&. , DN(&W &.'%(),-( [79F c YQQ\ FFFR >9I +% 22 , 222 )'.+(R KB c UQ >7B4R 9D$.
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% I.D&(:(=./%. =,'%0,'%&. 5%',(/(DD%&(D%R 0,(&'($(&%/($. ;%.<,/,# "==$):$'.$8 C(-%/('%HH.', 79 KB ?BG
M ID TEV#U in 10’ Ripetibili dopo 10’
>*%$ ,',.,&#$7
+&':$',I$':* W$) *%7
50mg 15’ dopo infusione UQ$) Y]N +(=( %-0*D%(-, 7(% YQQ $)Z+%,
-$,).#)&)&)
;(D,8 =$(, :&K$##&
U$)ZU$: [F,:(W,-\
!""#$$% ' 20’ !""#$$% )+Y' K@ ’ →5MUW
3'(,8&.,*',8 2C9 , %D&N,$%. $%(&.'+%&. 5.&N%.'%/$%, I,-/'%&(:.'% , F(='.O,-/'%&(:.'% 2=,'/,-D%(-, .'/,'%(D. %- =',D,-H. +% +%DD,H%(-, .('/%&. 9*':)*,'(,8&.,*',8 2-D*00%&%,-H. &.'+%.&. , DN(&W &.'%(),-( [79F c YQQ\ FFFR >9I +% 22 , 222 )'.+(R KB c UQ >7B4R 9D$.
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% I.D&(:(=./%. =,'%0,'%&. 5%',(/(DD%&(D%R 0,(&'($(&%/($. ;%.<,/,# "==$):$'.$8 C(-%/('%HH.', 79R KBR ?BG
M ID TEV#U ,' M’ Ripetibili dopo 10’
>*%$ ,',.,&#$7
+&':$',I$':* W$) *%7
50mg 15’ dopo infusione UQ$) i@Y]@YjN +(=( %-0*D%(-, 7(% YQQ $) _ ] O(:/,Z+%,
.#).#!%)&)&)
U$)ZU$: [2-+,'.:\
;(D,8 =$(, :&K$##& !""#$$% ' ())#*(+$% !""#$$% )+Y' E’ →5’
3'(,8&.,*',8 2C9 , %D&N,$%. $%(&.'+%&. 5.&N%.'%/$%, I,-/'%&(:.'% , F(='.O,-/'%&(:.'% 2=,'/,-D%(-, .'/,'%(D. %- =',D,-H. +% +%DD,H%(-, .('/%&. 9*':)*,'(,8&.,*',8 2-D*00%&%,-H. &.'+%.&. , DN(&W &.'%(),-( [79F c YQQ\ FFFR >9I +% 22 , 222 )'.+(R KB c UQ >7B4R 9D$.
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% I.D&(:(=./%. =,'%0,'%&. 5%',(/(DD%&(D%R 0,(&'($(&%/($. ;%.<,/,# "==$):$'.$8 C(-%/('%HH.', 79R KBR ?BG ?O%/.', <'*D&. D(D ,-D%(-, [>6?I? ;J6959\
>*%$ ,',.,&#$7
M ID TEV#U ,' K*#* 3+*%8+@+$+ ()*) P’
+&':$',I$':*7
EFP IDJR7 =#$ +: P=F00 (+ GV 2FB!>;K>$6 7 !F<,F>$K/
&!*$,!&)&)
;(D,8 =$(, :&K$##&
YQQ$)Z]Q$: [5'.-+./,\
!""#$$% ' KM5’ !""#$$% )+Y' E?’ →2MXW
3'(,8&.,*',8 ?$,'),-H, %=,'/,-D%O, 2=,'/,-D%(-, .'/,'%(D. %- =',D,-H. +% +%DD,H%(-, .('/%&. 9*':)*,'(,8&.,*',8 2-D*00%&%,-H. &.'+%.&. , DN(&W &.'%(),-( [79F c YQQ\ FFFR >9I +% 22 , 222 )'.+(R KB c UQ >7B4R 9D$.
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% I.D&(:(=./%. =,'%0,'%&. 5%',(/(DD%&(D%R 0,(&'($(&%/($. ;%.<,/,# "==$):$'.$8 C(-%/('%HH.', 79R KBR ?BG 2=(/,-D%(-, ('/(D/./%&. [=H D*=%-( =,' fN +(=( %-0*D%(-,\
>*%$ ,',.,&#$7
20mg (4ml) in 2’
>*%, %<88$%%,=$7
GHFXHID TQF16ml) in 2’ Ripetibili ogni 10’
+&':$',I$':*7
EFG IDJI,' T+"Y GQHHIDJ(,$U =#$ +: P=F00 (+ GV 2P>;K>$6 7 ,F$K/
"'&,'!2$-
;(D,8 O,+% /.<,::.
UQ$)ZU$: [9:/%.H,$R !""#$$% ' 3’ !""#$$% )+Y' 5’ ;%:H,-,R 5%:+%,$\ 3'(,8&.,*',8 .-)%-. %-D/.<%:,R .-)%-. +% 7%-H$,/.: 5.&N%&.'+%, FI +. '%,-/'( ↓ della FV nel flutter e nella FA
9*':)*,'(,8&.,*',8 2=(/,-D%(-,R F&($=,-D( &.'+%.&( V7V ['%D&N%( +% +,),-,'.H%(-, +% *-. K9 %- KI\ FFFR >F9R >9I +% )'.+( ,:,O./(
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% 3(- .DD(&%.', . <,/.@<:(&&.-/% [+$$#I*#Q# XUW *+;;+ :%:P#I:(%I#\ "==$):$'.$8 C(-%/('%HH.', 79R KBR ?BG
>*%$ ,',.,&#$7 HNEMFHNPH IDJLD ,' G’ Y 0: %- ]Q && +% FK
X@ TB ?@ TB L@ TB Z@ TB U@ TB [@ TB
KD?M? ); NML ); ND?MZ ); XDKMUDX ); ?ME@ ); ?D?MEK );
+&':$',I$':*7 HNEGFHNPH IDJLDJR U 0: %- ]UQ&& +% FK [Y$)Z$:\ ?ME@ );SW LMEK );SW ZME? );SW [MEU );SW E@MK@);SW ENMKL );SW
3$#!.!-'&
;(D,8 O,+% /.<,::.
U$)Z]$: [2D(=/%-\
!""#$$% ' E’ !""#$$% )+Y' ?ME?’→30’ MLW
3'(,8&.,*',8 .-)%-. %-D/.<%:,R .-)%-. +% 7%-H$,/.: 5.&N%&.'+%, FI +. '%,-/'( ↓ della FV nel flutter e nella FA
9*':)*,'(,8&.,*',8 2=(/,-D%(-,R F&($=,-D( &.'+%.&( V7V ['%D&N%( +% +,),-,'.H%(-, +% *-. K9 %- KI\ FFFR >F9R >9I +% )'.+( ,:,O./(
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% Epatopatia → ridurre i dosaggi M. di Duchenne → può precipitare insufficienza ',D=%'./('%. "==$):$'.$8 C(-%/('%HH.', 79 KB ?BG
>*%$ ,',.,&#$7 5mg (1fl) in 5’ ripetibile +&':$',I$':*7 EFMI8DJSDJI,' !F#$ +: P=F00 (+ GV 2PFF>0;K>$6 I8DJSDJI,' E G P X@ TB EK );SW KX );SW NL );SW ?@ TB E? );SW N@ );SW X? );SW L@ TB EU );SW NL );SW ?X );SW Z@ TB KE );SW XK );SW LN );SW U@ TB KX );SW XU );SW ZK );SW [@ TB KZ );SW ?X );SW UE );SW
M T+"YU L@ );SW Z? );SW [@ );SW E@? );SW EK@ );SW EN? );SW
0+#)/$-'"$
;(D,8 =$(, :&K$##&
]Q$)ZU$:d ]UQ$)Z]U$: [A.D%_\
!""#$$% ' '7.)(+$787A+):% '%:).7E 5’ (+?9%8+0)E 20’ !""#$$% )+Y' XMLW
3'(,8&.,*',8 ?79R ?$,'),-H, %=,'/,-D%O, 2-D*00%&%,-H. ',-.:,R %=,'` 9*':)*,'(,8&.,*',8 2=(/,-D%(-,R %=(O(:,$%. 9-*'%.
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% 2=(/,-D%(-, ;(--, %- ,/P 0,'/%:, "==$):$'.$8 C(-%/('%HH.', 79R KBR ?:,//'(:%/% [3.R `R B.R C)R B:\
Dosaggi nell’e($I& W*#I*'&)$ &8<:*7
X@ TB ?@ TB L@ TB Z@ TB U@ TB
HNMFE IDJSD ,' EI,' G% :): 9+.*):(% ()*) !=>+: G IDJSD ,' EI,' @D? )BSTB E )BSTB E ";a K "; E ] ` "; N "; K "; X "; K ] ` "; ? "; N "; L ";
a "; (I$#:+ A%)# "; *+ K@)B
K )BSTB X "; L "; U "; E@ "; EK ";
%',#)1&'4$#'%!
;(D,8 =$(, :&K$##&
U$)ZYRU$: [I,-%/'%-R 3%/'(D('<%+,\
!""#$$% ' E’ !""#$$% )+Y' EM?’ →5’
3'(,8&.,*',8 2C9 , %D&N,$%. $%(&.'+%&. F&($=,-D( &.'+%.&( &(- ?79 , 79 .:/. ?$,'),-H, %=,'/,-D%O,
9*':)*,'(,8&.,*',8 2=(/,-D%(-, IMA destro (↓ GC) Tamponamento cardiaco ed embolia polmonare (↓GC) ?$(''.)%. &,',<'.:,
>*%$ ,',.,&#$7 5mg (1fl) in 1’ +&':$',I$':*7 HNEFGI8DJSDJI,' ,#$ +: P=F00 (+ GV 2NF>0;K>$6 I8DJSDJI,' HNE HNGM E X@ TB X );SW E@ );SW X@ );SW ?@ TB ? );SW EKD? );SW ?@ );SW L@ TB L );SW E? );SW L@ );SW Z@ TB Z );SW EZD? );SW Z@ );SW U@ TB U );SW K@ );SW U@ );SW [@ TB [ );SW KKD? );SW [@ );SW "6@36" 1;"
G T+"YU U@ );SW E@@ );SW EK@ );SW EX@ );SW EL@ );SW EU@ );SW
E@);SW W ?M10ml/h ogni 5’ +: @7.% 7 5X % ()$)9% EZD? );SW W EZD?ml/h ogni 5’ +: @7.% 7 5X % (+.*:%7
%',#).#+//'!,)
;(D,8 =$(, :&K$##&
YQQ$)ZU$: [F(+%( -%/'(='*DD%./(\
!""#$$% ' ())#:*(+$% !""#$$% )+Y' ?’ →E@ ’
3'(,8&.,*',8 ?$,'),-H, %=,'/,-D%O, ;%DD,&.H%(-, .('/%&. F&($=,-D( &.'+%.&( &(- ?79 , 79 .:/.
9*':)*,'(,8&.,*',8 B(.'/.H%(-, .('/%&. 9/'(0%. (//%&. +% A,<,' 2C9 +,D/'( [↓ GC) Tamponamento cardiaco ed embolia polmonare (↓GC)
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% 2-D*00%&%,-H. ,=./%&.R ',-.:, , &,'<'(O.D&(:.', 2=(/%'(%+%D$( "==$):$'.$8 C(-%/('%HH.', 79R KBR ?BG 7'(/,)),', +.::. :*&, , +%:*%', %- FG UT
I8DJSDJI,' X@ TB L@ TB U@ TB [@ TB
>*%&DD,*7 EFEH I8DJSDJI,' ! #$ +: P=F00 (+ GU 2YFF>0;K>$6 E G M L );SW EK );SW N@ );SW [ );SW EU );SW X? );SW EK );SW KX );SW L@ );SW EN );SW KZ );SW LZ );SW
;*%%,K,#$ ,':*%%,8&.,*'$ (& B,*8,&'&:,
EH L@ );SW [@ );SW EK@ );SW EN? );SW
!-'%)0'&&'%!
;(D,8 =$(, :&K$##&
]gQ$)ZYQ$: [5,0.$%-R 9$%-($.:\
3'(,8&.,*',8 9D$. <'(-&N%.:, 9-/.)(-%D/. +,: ;%=%'%+.$(:(
!""#$$% ' 30’ !""#$$% )+Y' N@ML@ ’
9*':)*,'(,8&.,*',8 J:&,'. %- 0.D, .//%O.
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% F&($=,-D( &.'+%.&( ?=%:,DD%. "==$):$'.$8 C(-%/('%HH.', 79R KBR ?BG +(D.))% $%-('% D, /'.//./% &(- ,'%/'($%&%-.R &%$,/%+%-.R .::(=*'%-(:( [2-/,'.H%(-%\ 9-/.)(-%D/. &(- +%*',/%&% .-D.R <.'<%/*'%&%R &.'<.$.H,=%-.R D%$=./%&($%$,/%&%
>*%$ ,',.,&#$7 MF6 mg/kg in 20’ ] 0: %- YQQ&& +% FK
X@ TB ?@ TB L@ TB Z@ TB U@ TB [@ TB
UX );SW E@X );SW EKX );SW EXL );SW ELL );SW EUL );SW
+&':$',I$':*7 HNQFHNZ IDJLDJR ] 0: %- ]UQ&& +% FK [YRS] $)Z$:\ UMEU );SW E@MKN );SW EKMKZ );SW EXMNK );SW ELMNL );SW EUMX@ );SW
/)-!,)/,!,'%!
;(D,8 O,+% /.<,::.
]UQ$&) – f$)Z]$: [F/%:.$%-\ ]$)Z]$: [C(+*D/./%-.\
3'(,8&.,*',8 ?$(''.)%, .&*/, ).D/'%&N, ( +*(+,-.:% [*:&,',R O.'%&%\ ;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% ;%.<,/, %-D*:%-(@+%=,-+,-/, [=*b &.*D.', %=():%&,$%. D,)*%/. +. %=,'):%&,$%. +(=( ]@f (',\ "==$):$'.$8 2-%,H%(-, ,O :,-/.$,-/, &(- =.H%,-/, D*=%-(
4%:+BB(%' ND? )ABSTBSW P#Q XUMZKW → 120h (MAX) In pompa d’infusione !#$ (7 P>; +: =F00 (+ GV 2YF >0;K>$6 X@ TB ND? );SW ?@ TB XDX );SW L@ TB ?DK );SW Z@ TB LDE );SW U@ TB ZD@ );SW [@ TB ZD[ );SW
$.!#'%! /)"'4!
;(D,8 O,+% /.<,::.
]UQ$)ZU$: [Y$: L UQQQ J2\ 3'(,8&.,*',8
!""#$$% ' 3’ !""#$$% )+Y' 5’
?$<(:%. 7(:$(-.', ?$<(:%. .'/,'%(D. =,'%0,'%&. 9-)%-. %-D/.<%:,R 2C9 B2;
9*':)*,'(,8&.,*',8 ?$(''.)%. %- .//( G'.O, /'($<(&%/(=,-%. ['%D&N%( E25\
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +%
7./(:()%, ',-.:% 2=,'/,-D%(-, .'/,'%(D. -(- &(-/'(::./.
"==$):$'.$8
C(-%/('%HH.', .755 ()-% i (', [YRU@]RU O(:/,\ "6B3B5>58 F(:0./( +% ='(/.$%-. [MI# E[ W$) E I# (, $W&),'&\
>*%$ ,',.,&#$ TK*#*U7 EI# TMHHH C3U +&':$',I$':*7 =>$ 2P=FFF ZS6 +: =FF00 (+ GV 2=F ZSK>$6 3%)(IA(+Q# A%I K@);SW CE@@@ =-SWF ()*) N / 0):89)$$79% 75[[ % >)(+#+079% &;BB 2.%06
/*#*
OX@ X@MX[ ?@MZ? ZLMU? ULME@@ E@EME?@ JE?@
N@@@ =@ @ @ @ @ @
?:*W ,'V<%\ 2>+:?8+6 @ @ @ @ N@ L@ L@
2&)\ =$#*8 2>$K/6 ]K ]E /#::>I+ ME MK MN ML
0,W$:,.\ &;BB LW LW EKW EKW LW LW LW
,#)-*)&','4'
;(D,8 O,+% /.<,::.
3'(,8&.,*',8 2-0.'/( $%(&.'+%&( .&*/( F5?C2 ?$<(:%. =(:$(-.', &(- %$=,)-( ,$(+%-.$%&( 2&/*D %D&N,$%&(k
9*':)*,'(,8&.,*', D$'$)&#,8 2&/*D ,$(''.)%&( ( ,O,-/( &,',<'.:, ,-/'( E &''* 3,(=:.D%. %-/'.&'.-%&. ?$(''.)%. %- 0.D, .//%O. [/'.--, $,D/'*.H%(-%\ F(D=,//. +%DD,&.H%(-, .('/%&.
;)$8&<.,*',8 &.*/,:. %- =',D,-H. +% 2=,'/,-D%(-, -(- &(-/'(::./. [l YjQZYYQ $$E)\ 5'.*$./%D$( ',&,-/, []@g D,//%$.-,\ 2-/,'O,-/( &N%'*')%&( $.))%(', [c f D,//%$.-,\ 6%.-%$.H%(-, &.'+%(=(:$(-.', [c g D,//%$.-,\ ?$(''.)%. %-/,'-. ',&,-/, []@g D,//%$.-,\ 7*-/*', O.D&(:.'% -(- &($='%$%<%:% 7',&,+,-/, *D( +% D/',=/(&N%-.D% +. U )%('-% . ] .--% ='%$. [%- &.D( +% '%*/%:%HH( +% D/',=/(&N%-.D%\ G'.O%+.-H. J:&,'. =,=/%&. .//%O. 5'.//.$,-/( .-/%&(.)*:.-/, ('.:, %- &('D(
*nell’ictus ischemico dovrebbe essere eseguita solo da *%9.):7$% .*%0+7$+AA78) % *9%#%9+@+$>%:8% +: ?:7 .89)1% ?:+8 9*':)*,'(,8&.,*', nell’ictus ischemico8 ?/P ljQ ( c Yj .--% F/('%. +% %&/*D , +%.<,/, 2-D('),-H. +,% D%-/($% +. =%m +% P *)$ ( -(- -(/( Rapido miglioramento dei sintomi prima dell’infusione ?O,-/( +% )'.O, ,-/%/P [32EFFl]U\ Convulsioni all’insorgenza F%-/($% %-+%&./%O% +% ,$(''.)%. [.-&N, &(- 5B -,)./%O.\ F($$%-%D/'.H%(-, +% ,=.'%-. -,::, gj (', =',&,+,-/% 5,$=( +% /'($<(=:.D/%-. &N, D*=,'. % :%$%/% D*=,'%('% f 7%.D/'%-, c YQQQQQZ$$ 79lYjQZYYQ $$E) ( -,&,DD%/. +% /,'.=%. ,-+(O,-. =,' '%=('/.', :. 79 ,-/'( M*,D/% :%$%/% G:%&,$%. cUQ ( lgQQ$)Z+:
.37-6b;KPF>$ )**?9% =F>;K=F>$6 E’ possibile diluire ulteriormente in Soluzione Fisiologica -0. <7!0- #I$Q% L %Q# 2*9)8)0)$$) 700%$%978)6 G%;%
E? )B ?@ )B (I N@ )(I 5Q()( N@ )(I 5A \ N= O; → 0,75mg/Kg <>AA#::(\( N? )B (I L@ )(I L@ )(I Pz < 65 Kg → 0,=F>;KO; -0. <7!0- LMEK %Q# 2*9)8)0)$$) +: , )9%6 G%;% 5Q()( L@ )(I <>AA#::(\( EK@ )(I
E@ )B ?@ )B (I L@ )(I Pz < 65 Kg → 0,75mg/Kg X@ )B (I EK@ )(I Pz < 65 Kg → 0,=F>;KO; !)H%;(+ 5%;)%I+Q#
G%;%
E@ )B
-I">:(%I# [@ )B (I EK@ )(I .77!/1-2/!' Per la breve emivita (5’) accompagnare la .)>>+:+.897A+):% 7( H*79+:7 .)(+07 *%9 MP/ -A$>: (:AW#)(A% FB] >;KO; 2>7L ]F >;6 G%;%
E@c *#;;+ *%:#
-I">:(%I# [@c *#;;+ *%:# (I L@ )(I .77!/1-2/!' H'+879% 70+() 70%8+$.7$+0+$+0) ) %*79+:7 .)(+07 :%$$% *9+>% PY/ ()*) $7 89)>@)$+.+
